计算溶液所需的质量、体积或浓度。
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC 50 s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1 ,MMP-2, MMP-3 ,MMP-8,MMP-9, MMP-13 ,respectively.
In Vitro
XL-784 is a highly potent, low-molecular-weight (1,122 g/mol) inhibitor of MMPs that has very limited aqueous solubility (20 μg/mL). XL-784 potently inhibits MMP-2, MMP-13, and\nADAM10 [TNF-α-converting enzyme (TACE)] activity in vitro, with IC 50 values in the range of 1-2 nM. XL-784 also inhibits MMP-9 (IC 50 ~20 nM) activity and ADAM17 (IC 50 ~70 nM) also known as TACE. However, it exhibits low potency for inhibition of MMP-1 (IC 50 ~2,000 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
All mice tolerate the treatments similarly. Control mice all developed aneurysms with a mean %△AD of 158.5%±4.3%. Treatment with all doses of XL-784 and doxycycline are effective in inhibiting aortic dilatation. There is a clear dose-response relationship between XL-784 and reductions in aortic dilatation at harvest (50 mg/kg 140.4% ±3.2%; 125 mg/kg 129.3% ±5.1%; 250 mg/kg 119.2%±3.5%; all Ps <0.01 compared to control). This continues with the higher doses (375 mg/kg 88.6%±4.4%; 500 mg/kg 76.0%±3.5%). The highest 2 doses of XL-784 tested are more effective than doxycycline (112.2%±2.0%, P<0.05) in inhibiting maximal dilatation of the aorta after elastase perfusion. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice A total of 89 mice undergo aortic perfusion. Beginning the day of perfusion, animals are treated with the study drug (e.g., XL-784), a negative control, or doxycycline. 76 animals survive to sacrifice and are included in the analysis. Animals treated with the experimental agent, XL-784 , receive gavage daily with the agent diluted in 0.1 mL of Cremophor, a nonionic castor oil-based solubilizer and emulsifying agent. Three doses of the drug are used, 50 (n=17), 125 (n=17), and 250 mg/kg per d (n=18) administered as a single daily dose. The fifth group of mice do not receive a gavage treatment but are treated with doxycycline (n=19) in their drinking water at a concentration 100 mg/kg per d of the animals. In the second treatment protocol, a total of 50 animals underwent aortic perfusion and 47 animals survive for analysis at 14 days. The 5 treatment groups are XL-784 at 250, 375, or 500 mg/kg , Cremaphor diluent alone, or doxycycline 100 mg/kg. Animals are assigned in groups of 3 to a treatment group rotating randomly through each treatment group until there are 9 animals in each group except for the 500 mg/kg per d group which totaled to 14 animals . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:MMP-2 0.81 nM (IC 50 ) MMP13 0.56 nM (IC 50 ) MMP-8 10.8 nM (IC 50 ) MMP-9 18 nM (IC 50 ) MMP-3 120 nM (IC 50 ) MMP-1 1900 nM (IC 50 )
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 苯及其取代衍生物 |
| 亚类(Subclass) | 二苯醚 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 二苯醚 |
| 其他上位类(Alternative Parents) | 二芳醚 α氨基酸及其衍生物 苯磺酰胺类 哌嗪羧酸 哌嗪甲酰胺 苯磺酰基化合物 苯氧基化合物 酚醚 氯苯类 氟苯类 有机磺酰胺 芳基氯化物 芳基氟化物 磺酰基 氨基甲酸酯 异羟肟酸 氮杂环化合物 二烷基醚 羰基化合物 有机氮化合物 有机氧化物 有机氯化物 有机氟化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂单环化合物 |
| 取代基(Substituents) | 1,4-二氮杂环丁烷 - α-氨基酸或其衍生物 - 芳香族杂单环化合物 - 芳基氯化物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 苯磺酰胺 - 苯磺酰基 - 脲酸酯 - 羰基 - 羧酸衍生物 - 氯苯 - 二烷基醚 - 二芳基醚 - 二苯基醚 - 乙醚 - 氟萘 - 卤苯 - 烃衍生物 - 羟胺酸 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机磺酸或其衍生物 - 有机氯化物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 有机硫酰胺 - 有机磺酸或其衍生物 - 有机硫化合物 - 苯酚醚 - 苯氧基化合物 - 哌嗪 - 哌嗪-1-羧酸 - 哌嗪-2-甲酰胺 - 磺酰基 |
| 描述(Description) | 该化合物属于二苯醚类有机化合物。这类芳香化合物通过醚键连接两个苯环。 |
| 外部描述符(External Descriptors) | 暂无 |